Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).
Physical Properties:
White solid
Purity:
99% by HPLC NMR (Conforms)
Storage Temperature:
-20°
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
Shipping Code:
RT
Available Options
Size :
Quantity
5 mg
$65.00
25 mg
$150.00
Request Quote / Bulk / Custom Size
Product Inquiry
Ruxolitinib (941678-49-5) is a potent and selective JAK1/2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively.1 Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM).2 Inhibits the proinflammatory secretome of senescent cells.3 The JAK1 S646P mutant is highly sensitive to ruxolitinib.4Clinically useful cancer chemotherapeutic.
References/Citations:
1) Verstovsek et al. (2009), Therapeutic potential of JAK2 inhibitors; Hematology Am. Soc. Hematol. Educ. Program, 2009(1) 636 2) Quintas-Cardama et al. (2010), Preclinical characterization of the selective JAK1/2 inhibitor INCB01824: Therapeutic implications for the treatment of myeloproliferative neoplasms; Blood, 115 3109 3) Farr et al. (2017) Targeting cellular senescence prevents age-related bone loss in mice; Nat. Med. 23 1072 4) Li et al. (2017) Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia; Oncotarget 8 34687
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a restocking/refund fee
Ruxolitinib (941678-49-5) is a potent and selective JAK1/2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively.1 Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM).2 Inhibits the proinflammatory secretome of senescent cells.3 The JAK1 S646P mutant is highly sensitive to ruxolitinib.4Clinically useful cancer chemotherapeutic.
References/Citations:
1) Verstovsek et al. (2009), Therapeutic potential of JAK2 inhibitors; Hematology Am. Soc. Hematol. Educ. Program, 2009(1) 636 2) Quintas-Cardama et al. (2010), Preclinical characterization of the selective JAK1/2 inhibitor INCB01824: Therapeutic implications for the treatment of myeloproliferative neoplasms; Blood, 115 3109 3) Farr et al. (2017) Targeting cellular senescence prevents age-related bone loss in mice; Nat. Med. 23 1072 4) Li et al. (2017) Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia; Oncotarget 8 34687
Related Products
Dilution Calculator
Molarity Calculator
Related Products
Dilution Calculator
Molarity Calculator
Calculate the molar concentration, mass or volume in a solution.